Analyzing Blood Samples for Glioma Diagnosis
Pilot Study of Liquid Biopsy as a Diagnostic Tool for Gliomas by Analyzing Circulating Tumor DNA in Blood Samples, and Its Validation With the Corresponding Tissue Biopsies.
This study is testing a new blood test to see if it can help diagnose gliomas in patients with brain lesions by looking for tumor DNA in their blood instead of using traditional tissue biopsies.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 10 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Corporacion Parc Tauli Academic / other |
| Locations | 1 site (Sabadell, Barcelona) |
| Trial ID | NCT05964153 on ClinicalTrials.gov |
What this trial studies
This pilot study investigates a new liquid biopsy approach for diagnosing gliomas by detecting circulating tumor DNA (ctDNA) in the blood of patients with brain lesions. The study utilizes minimally invasive blood sampling and employs digital PCR to enhance sensitivity in detecting ctDNA. The results from blood samples will be compared to tissue biopsies to assess the reliability of this method. The goal is to standardize a protocol for glioma diagnosis that could be beneficial for patients with challenging tumor locations.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with a primary brain lesion compatible with glioma as seen on MRI.
Not a fit: Patients who are pregnant, breastfeeding, or have a different diagnosis than glioma will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could provide a less invasive and more accurate method for diagnosing gliomas.
How similar studies have performed: Other studies have shown promise in using liquid biopsy techniques for cancer diagnosis, indicating potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years. * De novo primary brain lesion, compatible with a glioma according to contrast-enhanced magnetic resonance images. The injury must be treated by the usual surgical procedure. * Signature of informed consent. Exclusion Criteria: * Pregnant or breastfeeding women. * Reasonable doubts in the diagnosis of glioma by magnetic resonance, or patients whose tissue biopsy diagnoses a brain lesion other than a glioma. * Patients who cannot undergo surgical resection, or when the tissue samples taken are not significant enough to be analyzed. * Inability or disagreement with signing the informed consent.
Where this trial is running
Sabadell, Barcelona
- Hospital Universitari Parc Taulí — Sabadell, Barcelona, Spain (Recruiting)
Study contacts
- Principal investigator: Silvia Gil — Hospital Universitari Parc Taulí
- Study coordinator: Coloma Moreno
- Email: cmoreno@tauli.cat
- Phone: +34937231010
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.